Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines.

The Journal of infection（2023）

引用 3|浏览34

暂无评分

摘要

27841311 EudraCT:2021-001275-16 FUNDING: UK Vaccine Task Force (VTF), Coalition for Epidemic Preparedness Innovations (CEPI) and National Institute for Health and Carte Research (NIHR). NVX was supplied for trial use by Novavax, Inc.

查看译文

关键词

Covid,Protein,SARS-CoV2,T cell,T-cell,Tcell,adenovirus vector,adjuvant,antibody,cellular,heterologous,homologous,humoral,immunology,mRNA lipid nanoparticle,persistence,subgroup,vaccination,vaccine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要